stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) Revenue growth
Twist Bioscience Corporation's revenue growth over the twelve months to 30 June 2026 was 19.2%, down 1.1 percentage points from fiscal 2025 (20.3%). Over the past ten years it has ranged from −78.9% (fiscal 2016) to 374.5% (fiscal 2017); the current reading is higher than 20% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 20.3% | (7.37) |
| FY2024 | 27.7% | 7.28 |
| FY2023 | 20.4% | (33.42) |
| FY2022 | 53.8% | 6.96 |
| FY2021 | 46.9% | (18.80) |
| FY2020 | 65.7% | (48.22) |
| FY2019 | 113.9% | (22.27) |
| FY2018 | 136.2% | (238.37) |
| FY2017 | 374.5% | 453.46 |
| FY2016 | −78.9% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 23.2% | 3.93 |
| Mar 2026 | 19.3% | 2.42 |
| Dec 2025 | 16.9% | 0.01 |
| Sep 2025 | 16.9% | (1.03) |
| 31 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IBRX ImmunityBio, Inc. compare | 192.9% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 92.8% |
| TGTX TG Therapeutics, Inc. compare | 76.1% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| PTGX Protagonist Therapeutics, Inc. compare | 34.8% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| KRYS Krystal Biotech, Inc. compare | 26.0% |
| TWST Twist Bioscience Corporation | 19.2% |
| SYRE Spyre Therapeutics, Inc. compare | −81.8% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TWST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement